Validity and Reproducibility of a New Treadmill Protocol: The Fitkids Treadmill Test. Med. Sci. Sports Exerc., Vol. 47, No. 10, pp. 2241–2247, 2015. Purpose: This study aimed to investigate the validity and reproducibility of a new treadmill protocol in healthy children and adolescents: the Fitkids Treadmill Test (FTT). Methods: Sixty-eight healthy children and adolescents (6–18 yr) were randomly divided into a validity group (14 boys and 20 girls; mean T SD age, 12.9 T 3.6 yr) that performed the FTT and Bruce protocol, both with respiratory gas analysis within 2 wk, and a reproducibility group (19 boys and 15 girls; mean T SD age, 13.5 T 3.5 yr) that performed the FTT twice within 2 wk. A subgroup of 21 participants within the reproducibility group performed both FTT with respiratory gas analysis. Time to exhaustion (TTE) was the main outcome of the FTT. Results: V˙ O2peak measured during the FTT showed excellent correlation with V˙ O2peak measured during the Bruce protocol (r = 0.90; P G 0.01). Backward multiple regression analysis provided the following prediction equations for V˙ O2peak (LIminj1) for boys and girls, respectively: V˙ O2peak FTT ¼ j0:748 þ ð0:117 TTEFTTÞ þ ð0:032 bodymassÞ þ 0:263, and V˙ O2peak FTT ¼ j0:748 þ ð0:117 TTEFTTÞ þ ð0:032 bodymassÞ [R2 ¼ 0:935; SEE ¼ 0:256LI min j1]. Cross-validation of the regression model showed an R2 value of 0.76. Reliability statistics for the FTT showed an intraclass correlation coefficient of 0.985 (95% confidence interval, 0.971–0.993; P G 0.001) for TTE. Bland–Altman analysis showed a mean bias of j0.07 min, with limits of agreement between +1.30 and j1.43 min. Conclusions: Results suggest that the FTT is a useful treadmill protocol with good validity and reproducibility in healthy children and adolescents. Exercise performance on the FTT and body mass can be used to adequately predict V˙ O2peak when respiratory gas analysis is not available.
A systematic review with meta-analysis was conducted to assess the prevalence of automatically listing (a) senior member(s) of a department as co-author(s) on all submitted articles in health sciences and the prevalence of degrees of support on a 5-point justification scale. Survey research was searched in PubMed, Lens.org, and Dimensions.ai. until January 5 2023. We assessed the methodological quality of studies and conducted quantitative syntheses. We identified 15 eligible surveys, that provided 67 results, all of which were rated as having low quality. A pooled estimate of 20% [95% CI 16–25] (10 surveys, 3619 respondents) of researchers in various health sciences reported that a senior member of their department was automatically listed as an author on all submitted articles. Furthermore, 28% [95% CI 22–34] of researchers (10 surveys, 2180 respondents) felt that this practice was ‘never’, 24% [95% CI 22–27] ‘rarely’, 25% [95% CI 23–28] ‘sometimes’, 13% [95% CI 9–17] ‘most of the time’, and 8% [95% CI 6–9] ‘always justified’. The practice of automatically assigning senior members of departments as co-authors on all submitted manuscripts may be common in the health sciences; with those admitting to this practice finding it unjustified in most cases.Registration of the protocol The protocol was registered in Open Science Framework. Link: https://osf.io/4eywp/.
MULTIFILE
Organ-on-a-chip technology holds great promise to revolutionize pharmaceutical drug discovery and development which nowadays is a tremendously expensive and inefficient process. It will enable faster, cheaper, physiologically relevant, and more reliable (standardized) assays for biomedical science and drug testing. In particular, it is anticipated that organ-on-a-chip technology can substantially replace animal drug testing with using the by far better models of true human cells. Despite this great potential and progress in the field, the technology still lacks standardized protocols and robust chip devices, which are absolutely needed for this technology to bring the abovementioned potential to fruition. Of particular interest is heart-on-a-chip for drug and cardiotoxicity screening. There is presently no preclinical test system predicting the most important features of cardiac safety accurately and cost-effectively. The main goal of this project is to fabricate standardized, robust generic heart-on-a-chip demonstrator devices that will be validated and further optimized to generate new physiologically relevant models to study cardiotoxicity in vitro. To achieve this goal various aspects will be considered, including (i) the search for alternative chip materials to replace PDMS, (ii) inner chip surface modification and treatment (chemistry and topology), (iii) achieving 2D/3D cardiomyocyte (long term) cell culture and cellular alignment within the chip device, (iv) the possibility of integrating in-line sensors in the devices and, finally, (v) the overall chip design. The achieved standardized heart-on-a-chip technology will be adopted by pharmaceutical industry. This proposed project offers a unique opportunity for the Netherlands, and Twente in particular, which has relevant expertise, potential, and future perspective in this field as it hosts world-leading companies pioneering various core aspects of the technology that are relevant for organs-on-chips, combined with two world-leading research institutes within the University of Twente.
Climate change and the depletion of resources in the world are widely recognized as the greatest societal challenges. The building sector is responsible for 40% of the raw material consumption globally. The emissions related to construction materials are anticipated to double by 2050, if no new technologies are adopted (EC, 2021). Based on the environmental cost indicator, isolation has the second largest (after concrete) impact to the environment. In Mythic - Myterials for THermal Insulation in Construction goal is to develop (in co-creation with the work field) the best available mycelium biocomposite, which can be used as a circular, biodegradable insulation material for construction in the building sector. In recent research projects partners concluded that Mycelium biocomposites have a high potential to replace traditional fossil-based isolation materials, but further research on the thermal insulation and moisture absorption is needed to convince the construction market. In the project various partners will cooperate, both from the production side of mycelium composites, as well as from the application side. Some partners originate from previous projects, but others contacted Centre of Expertise for the Biobased Economy (CoEBBE) to build further on the existing network. There are several SME’s from the Netherlands, but also from abroad (Nylausn from Iceland, Mogu Srl from Italy and Corstyrene form France), as well as Branche organizations and knowledge institutes. Avans works together with HZ in CoEBBE and for the microbiological knowledge we cooperate with the University of Utrecht. For the market research CoEBBE cooperates with the lectorate New Marketing within Avans, focussing on sustainability via biomimicry. Mycelium composites and natural products for the building industry is the theme that binds all partners.
